You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 168 No. 8, April 28, 2008 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Editorial
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (5)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Cardiovascular System
 •Rheumatology
 •Osteoporosis
 •Women's Health
 •Women's Health, Other
 •Arrhythmias
 •Drug Therapy
 •Adverse Effects
 •Endocrine Diseases
 •Diabetes Mellitus
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Considering Competing Risks . . . Not All Black and White

Jane A. Cauley, DrPH; Kristine E. Ensrud, MD, MPH

Arch Intern Med. 2008;168(8):793-795.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The world is not black and white. More like black and gray.
—Graham Greene

Osteoporosis and type 2 diabetes mellitus (DM), 2 of the most common chronic conditions, represent major public health burdens. The lifetime risk of an osteoporotic fracture ranges from 40% to 50% in women and from 13% to 22% in men.1-2 The goal of osteoporosis treatment is to reduce fractures because fractures cause significant morbidity and mortality. Diabetes mellitus affects 7% of the US population, or 20.8 million people.3 The goal of glucose-lowering treatment is to reduce long-term microvascular and macrovascular complications of the disease. Pharmacologic options for the treatment of osteoporosis and type 2 DM have expanded exponentially during the past decade.4-5 Trials in osteoporosis have demonstrated a reduction in risk of fracture with pharmacologic treatment. Trials in type 2 DM have demonstrated improvement in glycemic control . . . [Full Text of this Article]

STRENGTH


CONSISTENCY

BIOLOGICAL PLAUSIBILITY

TEMPORALITY

SPECIFICITY

CONCLUSIONS

AUTHOR INFORMATION


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Use of Thiazolidinediones and Fracture Risk
Christian Meier, Marius E. Kraenzlin, Michael Bodmer, Susan S. Jick, Hershel Jick, and Christoph R. Meier
Arch Intern Med. 2008;168(8):820-825.
ABSTRACT | FULL TEXT  

Use of Alendronate and Risk of Incident Atrial Fibrillation in Women
Susan R. Heckbert, Guo Li, Steven R. Cummings, Nicholas L. Smith, and Bruce M. Psaty
Arch Intern Med. 2008;168(8):826-831.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Patient Who Falls: "It's Always a Trade-off"
Tinetti and Kumar
JAMA 2010;303:258-266.
ABSTRACT | FULL TEXT  

Alendronate, Osteoporosis, and Atherosclerosis
Strandberg
Arch Intern Med 2008;168:2386-2387.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.